Хайлтын үр дүнгүүд - Alan Nicholas
- 7-н 1 - 7 үр дүнгүүдийг харуулж байна
-
1
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial -н Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo
Хэвлэсэн 2022Artigo -
2
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study -н Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Nuhad K. Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P. Kirschbrown, Priya Kumthekar
Хэвлэсэн 2021Artigo -
3
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 -н Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann‐Lii Cheng, Norelle R. Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, В. В. Бредер
Хэвлэсэн 2024Artigo -
4
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) -н Herbert I. Hurwitz, Benjamin Tan, James A. Reeves, Henry Xiong, Brad Somer, Heinz‐Josef Lenz, Howard S. Höchster, Frank A. Scappaticci, John F. Palma, Richard Price, John J. Lee, Alan Nicholas, Nicolas Sommer, Johanna C. Bendell
Хэвлэсэн 2018Artigo -
5
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma -н Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn
Хэвлэсэн 2021Artigo -
6
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant thera... -н Valerie W. Rusch, Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura, Dan J. Raz, Karen L. Reckamp, Robert E. Merritt, Dwight H. Owen, David J. Finley, Ciaran McNamee, Justin D. Blasberg, Edward B. Garon, John D. Mitchell, Robert C. Doebele, Frank A. Baciewicz, Misako Nagasaka, Harvey I. Pass, Katja Schulze, Ann Johnson, Paul A. Bunn, Bruce E. Johnson, Mark G. Kris, David J. Kwiatkowski, Ignacio I. Wistuba, Jamie E. Chaft, David P. Carbone, Jay M. Lee
Хэвлэсэн 2022Artigo -
7
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial -н Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michał Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica M. Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric M. Toloza, Eric B. Haura, Ciaran McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David Ross Camidge, Jennifer W. Carlisle, Justin D. Blasberg
Хэвлэсэн 2022Artigo
Хайх хэрэгслүүд:
Холбогдох сэдвүүд
Cancer
Internal medicine
Medicine
Oncology
Atezolizumab
Chemotherapy
Immunotherapy
Surgery
Bevacizumab
Clinical endpoint
Nivolumab
Clinical trial
Hepatocellular carcinoma
Randomized controlled trial
Sorafenib
Adverse effect
Breast cancer
Gastroenterology
Lung cancer
Phases of clinical research
Brain metastasis
Colorectal cancer
Confidence interval
Environmental health
FOLFIRI
FOLFOX
Folinic acid
Hazard ratio
Irinotecan
Liver function